pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)
pertuzumab, trastuzumab, and hyaluronidase-zzxf is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2020
Reference approved
Reference product
Phesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf
Genentech, Inc.
- Approved
- Jun 29, 2020
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for pertuzumab, trastuzumab, and hyaluronidase-zzxf, in chronological order.
Reference approval
Approval date of the reference pertuzumab, trastuzumab, and hyaluronidase-zzxf product.
6 yr ago
Frequently asked questions
Are there biosimilars approved for pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)?
No 351(k) biosimilars or interchangeable biosimilars referencing pertuzumab, trastuzumab, and hyaluronidase-zzxf are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.